Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
CSPC Pharmaceutical Group ( (HK:1093) ) has provided an update.
CSPC Pharmaceutical Group Limited has entered into an exclusive license agreement with Cipla USA, Inc. for the commercialization of its Irinotecan Liposome Injection in the United States. This agreement includes an upfront payment of $15 million to CSPC, with potential milestone payments and royalties based on sales. This strategic partnership is expected to enhance CSPC’s market presence in the U.S. and potentially increase its revenue through milestone and royalty payments.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$10.26 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group Limited is a Hong Kong-based company operating in the pharmaceutical industry, focusing on the development and commercialization of innovative drugs. The company utilizes a liposome technology platform to create products such as the Irinotecan Liposome Injection, which is used in the treatment of various solid tumors.
Average Trading Volume: 144,611,316
Technical Sentiment Signal: Hold
Current Market Cap: HK$63.24B
Learn more about 1093 stock on TipRanks’ Stock Analysis page.